



DOCKET # PF-0027 US

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on 3/14/97.

By: Jeremy Garcia

Printed: Jeremy Garcia

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Coleman et al.) Group Art Unit: 1807
Serial No.: 08/390,740)
Filed: February 17, 1995)
Title: NEW CHEMOKINES EXPRESSED IN PANCREAS)

AMENDMENT TRANSMITTAL FEE SHEET

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.

MAR 20 1997
CPT: JG

Claims	Claims After Amendment	-	Claims Previously Paid For	=	Present Extra	Other Than Small Entity Rate	Fee	Additional Fee(s)
Total Claims	12	-	25	=	-0-	\$22		\$ -0-
Indep. Claims	2	-	8	=	-0-	\$80		\$ -0-
<u>First Presentation of Multiple Dependent Claim</u>							<u>+\$260</u>	<u>\$ -0-</u>

TOTAL \$ -0-

No additional fee is required.
 Fee for Request for Extension of Time (one month) \$ 110.00
 Please charge Deposit Account No. 09-0108 the amount of \$ 110.00

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Lucy J. Billings
Lucy J. Billings
Reg. No. 36,749

Date: March 14, 1997
3174 Porter Drive
Palo Alto, California 94304
Phone: (415) 855-0555
Fax: (415) 845-4166

amendtra.lrg



**EXPEDITED PROCEDURE
EXAMINING GROUP 1807**

DOCKET # PF-0027 US

I hereby certify that this correspondence is being deposited with the United States Post Office Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on 3/14/97

By: Jeremy Garcia

Printed: Jeremy Garcia

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Assistant Commissioner for Patents
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR 1.116

Sir:

In response to the Final Office Action dated November 15, 1996, the period for responding having been extended by the accompanying Petition and fee, Applicants request reconsideration of the above-referenced patent application in view of the following amendments and remarks.

IN THE CLAIMS

The original pending claims are as follows:

1. (Reiterated) An isolated polynucleotide comprising a nucleic acid sequence encoding the polypeptide having the sequence as shown in SEQ ID NO:2.

5. (Reiterated) An expression vector comprising the polynucleotide of claim 1